Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?
- PMID: 19997690
- DOI: 10.2340/00015555-0749
Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?
Abstract
Hidradenitis suppurativa (HS) is a recurrent, debilitating suppurative skin disease. Nowadays the major challenge is the choice of optimal treatment. Many conservative therapies seem to have only a supportive character and do not prevent progression of the disease. Early surgical intervention with complete excision of the involved areas is still considered to be the most efficient therapy, but anti-tumour necrosis factor (TNF)-alpha agents may offer a possible non-surgical treatment. The aim of this study was to determine the serum concentration of TNF-alpha and its probable alterations during the disease process in patients with HS. Analysis of TNF-alpha serum concentration in 54 individuals with HS revealed significantly higher levels than in the sera of healthy controls (p = 0.006). To the best of our knowledge, this is the first report of increased TNF-alpha serum concentration in patients with HS.
Similar articles
-
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.Br J Dermatol. 2011 Jun;164(6):1292-8. doi: 10.1111/j.1365-2133.2011.10254.x. Epub 2011 May 17. Br J Dermatol. 2011. PMID: 21332464
-
Etanercept: effective in the management of hidradenitis suppurativa.Br J Dermatol. 2006 Apr;154(4):726-9. doi: 10.1111/j.1365-2133.2005.07067.x. Br J Dermatol. 2006. PMID: 16536817
-
Tumour necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh scores.Int J Clin Pract. 2006 Sep;60(9):1075-9. doi: 10.1111/j.1742-1241.2006.00936.x. Int J Clin Pract. 2006. PMID: 16939549
-
[Treatment options in severe hidradenitis suppurativa].Ned Tijdschr Geneeskd. 2011;155:A1912. Ned Tijdschr Geneeskd. 2011. PMID: 21426594 Review. Dutch.
-
Hidradenitis suppurativa: the role of immune dysregulation.Int J Dermatol. 2014 Oct;53(10):1186-96. doi: 10.1111/ijd.12550. Epub 2014 Jun 25. Int J Dermatol. 2014. PMID: 24961484 Review.
Cited by
-
Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa.JAMA Dermatol. 2020 Jan 1;156(1):65-71. doi: 10.1001/jamadermatol.2019.3412. JAMA Dermatol. 2020. PMID: 31721983 Free PMC article.
-
Hidradenitis suppurativa: infection, autoimmunity, or both?Ther Adv Musculoskelet Dis. 2019 Dec 30;11:1759720X19895488. doi: 10.1177/1759720X19895488. eCollection 2019. Ther Adv Musculoskelet Dis. 2019. PMID: 31908656 Free PMC article. Review.
-
Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa.JAMA Dermatol. 2019 Jul 1;155(7):797-802. doi: 10.1001/jamadermatol.2019.0164. JAMA Dermatol. 2019. PMID: 30994865 Free PMC article.
-
Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn's Disease?Clin Exp Gastroenterol. 2020 Aug 19;13:293-298. doi: 10.2147/CEG.S263685. eCollection 2020. Clin Exp Gastroenterol. 2020. PMID: 32943900 Free PMC article.
-
Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease.Dig Dis Sci. 2018 Mar;63(3):755-760. doi: 10.1007/s10620-018-4919-5. Epub 2018 Jan 22. Dig Dis Sci. 2018. PMID: 29357084
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical